uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
Show others and affiliations
2010 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 375, no 9725, 1536-1544 p.Article in journal (Refereed) Published
Abstract [en]


Lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory enzyme expressed in atherosclerotic plaques, is a therapeutic target being assessed in trials of vascular disease prevention. We investigated associations of circulating Lp-PLA2 mass and activity with risk of coronary heart disease, stroke, and mortality under different circumstances.


With use of individual records from 79 036 participants in 32 prospective studies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we did a meta-analysis of within-study regressions to calculate risk ratios (RRs) per 1 SD higher value of Lp-PLA2 or other risk factor. The primary outcome was coronary heart disease.


Lp-PLA2 activity and mass were associated with each other (r=0·51, 95% CI 0·47–0·56) and proatherogenic lipids. We noted roughly log-linear associations of Lp-PLA2 activity and mass with risk of coronary heart disease and vascular death. RRs, adjusted for conventional risk factors, were: 1·10 (95% CI 1·05–1·16) with Lp-PLA2 activity and 1·11 (1·07–1·16) with Lp-PLA2 mass for coronary heart disease; 1·08 (0·97–1·20) and 1·14 (1·02–1·27) for ischaemic stroke; 1·16 (1·09–1·24) and 1·13 (1·05–1·22) for vascular mortality; and 1·10 (1·04–1·17) and 1·10 (1·03–1·18) for non-vascular mortality, respectively. RRs with Lp-PLA2 did not differ significantly in people with and without initial stable vascular disease, apart from for vascular death with Lp-PLA2 mass. Adjusted RRs for coronary heart disease were 1·10 (1·02–1·18) with non-HDL cholesterol and 1·10 (1·00–1·21) with systolic blood pressure.


Lp-PLA2 activity and mass each show continuous associations with risk of coronary heart disease, similar in magnitude to that with non-HDL cholesterol or systolic blood pressure in this population. Associations of Lp-PLA2 mass and activity are not exclusive to vascular outcomes, and the vascular associations depend at least partly on lipids.


UK Medical Research Council, GlaxoSmithKline, and British Heart Foundation.

Place, publisher, year, edition, pages
2010. Vol. 375, no 9725, 1536-1544 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-198133DOI: 10.1016/S0140-6736(10)60319-4PubMedID: 20435228OAI: oai:DiVA.org:uu-198133DiVA: diva2:615300

Jonas Oldgren (UCR-Uppsala Clinical Research center & Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden) contributed to this study.

Available from: 2013-04-09 Created: 2013-04-09 Last updated: 2013-04-10Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Thompson, Alexander
In the same journal
The Lancet
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 131 hits
ReferencesLink to record
Permanent link

Direct link